AstraZeneca: two drugs approved in Japan

(CercleFinance.com) - This morning AstraZeneca announced that Tezspire (tezepelumab) has been approved by the Japanese health authorities as a treatment for asthma in patients whose disease symptoms cannot be controlled with inhaled corticosteroids and other long-term maintenance therapies.


The Japanese health authorities relied on a phase III study, in which Tezspire demonstrated superiority over placebo on all key primary and secondary endpoints, the group said.

Through clinical trials, Tezspire has demonstrated significant results in a large population of severe asthma patients, and with this approval, physicians can now offer patients in Japan a significant new treatment option, a related medical professional said.

In addition, AstraZeneca reports that Koselugo (selumetinib) has also been approved in Japan for the treatment of patients as from 3 years old with plexiform neurofibromas (PNs) in neurofibromatosis type 1 (NF1) with clinical symptoms (such as pain and disfigurement) and PNs that cannot be completely removed surgically without risk of significant morbidity.


Copyright (c) 2022 CercleFinance.com. All rights reserved.